Binance purchased $100 million worth of Circle shares, acquiring 1.24 million shares at $80.84 each through a private placement that closed on September 17. Under a new five-year partnership, Circle will pay Binance monthly fees based on USDC stablecoin holdings via its wallet service, while Binance will promote USDC on its platform. Binance cannot sell or transfer the shares for up to two years but retains voting rights. This deal expands their existing collaboration and replaces previous agreements set to expire in 2024 and 2025, with provisions allowing early termination under certain conditions.
Binance's $100 million Circle stake deal provides context for cryptocurrency market activity. For readers following crypto, here is Pluang's market snapshot as of Sep 22, 2026 18:03 WIB: Among 50 major cryptocurrencies priced on Pluang, 28 rose and 21 fell. Notable movers include XNO at Rp7.682 with a 21.28% increase, ONE at Rp63 down 20.29%, and COTI at Rp269 down 18.55%.
Graphene Manufacturing Group Ltd. secured approximately US$10 million through a private placement by issuing 6.47 million shares at CA$2.15 each, pending TSX Venture Exchange approval. The funds will be used to scale up graphene and battery cell prod...
Qualcomm will pay a dividend of $0.92 per share on September 24 to shareholders who owned the stock before September 3. This payout rewards investors with a significant return, though owning enough shares for a large payment requires substantial inve...
VICI Properties Inc. is expected to face increased refinancing costs as its upcoming debt maturities may be repriced significantly above current fixed rates. The company's rent escalators, mostly capped, may not keep pace with inflation if it stays a...
Tempus AI reported a 22% revenue increase in Q2 2026, improved profit margins, and raised its full-year guidance despite ongoing operating losses. The company’s acquisition of Personalis addresses a crucial gap in minimal residual disease (MRD) monit...
Viking Therapeutics reported that VK2735, a dual GLP-1/GIP receptor agonist, achieved up to 22% placebo-adjusted weight loss by week 33 in a study with no weight loss plateau observed. The drug maintained up to 97% of weight loss with every-other-wee...
